McKesson Corporation vs QUALCOMM, Inc. — how do they compare? McKesson Corporation trades at $825.15 (market cap $97.35B), while QUALCOMM, Inc. trades at $173.89 (market cap $179.52B). The key difference: QUALCOMM, Inc. is the larger of the two by market cap, and QUALCOMM, Inc. pays the higher dividend (2.16%). Which is the better fit depends on your goals.
| MCK | QCOM | |
|---|---|---|
Market Cap | $97.35B | $179.52B |
Sector | Health | Technology |
52-Week High | $995.69 | $251.10 |
52-Week Low | $659.01 | $124.07 |
Enterprise Value | $101.98B | $184.99B |
Dividend Yield | 0.39% | 2.16% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Qualcomm (QCOM) trades at $171.78, up 0.64% with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 54.8% gross margins and 22.31% net income margins, though revenue growth remains modest. Recent news highlights Qualcomm's AI and data center expansion efforts while facing smartphone market headwinds and increased competition from Nvidia's PC chip entry.
The stock presents a mixed outlook with attractive valuation (P/E 18.31) and analyst consensus target of $228.22 offering 33% upside potential. However, margin pressures and competitive threats from Nvidia's market expansion create near-term uncertainty. Institutional sentiment leans neutral with 50% hold ratings, suggesting cautious optimism about Qualcomm's diversification strategy.
Trailing returns across standard periods
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →